Syros Pharmaceuticals, a blood cancer treatment developer, receives a "Hold" rating with a $3.33 target price.

Syros Pharmaceuticals, a biopharmaceutical company focused on treating blood cancers, has received an average "Hold" rating from analysts, with a target price of $3.33. Its lead products include Tamibarotene for myelodysplastic and acute myeloid leukemia, SY-2101 for acute promyelocytic leukemia, and SY-5609 for advanced solid tumors. The company's stock is anticipated to report earnings on March 26th.